Puma Biotechnology Inc (PBYI) : The total money flow in Puma Biotechnology Inc (PBYI) was negative ($2.18 million), which signals selling by the traders on Fridays session. They trimmed their holdings by selling the stock on downticks to the tune of $23.07 million. In comparison, the inflow of money into the stock on upticks was $20.89 million. The uptick to downtick ratio was 0.91. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $3.22 million. The value of transactions on uptick was $2.94 million. The negative money flow of ($0.28 million) confirms the selling in Puma Biotechnology Inc (PBYI) on strength. The uptick to downtick ratio of block trades was 0.91. Puma Biotechnology Inc (PBYI) gained $6.48 at $41, a gain of 18.77% over the previous days close. However, the stock registered 24.32% in the week.
Puma Biotechnology Inc (PBYI) : 3 investment research analysts covering Puma Biotechnology Inc (PBYI) have an average price target of $55.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $70 and the lowest target is $36 for the short term. Analysts expect the variance to be within $17.47 of the average price.
Puma Biotechnology Inc (NYSE:PBYI): stock turned positive on Friday. Though the stock opened at $39.7, the bulls momentum made the stock top out at $42.28 level for the day. The stock recorded a low of $38.8 and closed the trading day at $41.52, in the green by 20.28%. The total traded volume for the day was 2,749,969. The stock had closed at $34.52 in the previous days trading.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (SR VP, CLINICAL RESEARCH & DEV) of Puma Biotechnology, Inc., Bryce Richard Paul had sold 3,000 shares worth of $330,090 in a transaction dated July 6, 2015. In this transaction, 3,000 shares were sold at $110.03 per share.
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the acquisition, development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.